Antisense Therapeutics Limited
Antisense Therapeutics Limited (ATHJF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
athjf · pe ratio · data through Jun 30, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Antisense Therapeutics Limited (ATHJF) measures how much investors pay for each dollar of the company's trailing earnings. ATHJF's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.01.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-06-30
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Antisense Therapeutics LimitedYou ATHJF | $20M | N/A | — | -$0.01 |
 Biofrontera AG BFFTF | $19M | N/A | — | -$13.02 |
 TPCO Holding Corp. GRAMF | $20M | N/A | — | -$2.32 |
 Kadimastem Ltd KMSTF | $10M | N/A | — | -$6.32 |
 Lifeist Wellness Inc. NXTTF | $16M | N/A | — | — |
 Organicell Regenerative Medicine, Inc. OCEL | $20M | N/A | — | -$0.86 |
 Simply Better Brands Corp. PKANF | $15M | N/A | — | -$0.36 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-06-30Latest FY2024 | — | $-0.01 | — | |
2023-06-30 FY2023 | — | $-0.02 | — | |
2022-06-30 FY2022 | — | $-0.01 | — | |
2021-06-30 FY2021 | — | $-0.01 | — | |
2020-06-30 FY2020 | — | $-0.01 | — | |
2019-06-30 FY2019 | — | $-0.01 | — | |
2018-06-30 FY2018 | — | $-0.01 | — | |
2017-06-30 FY2017 | — | $-0.02 | — | |
2016-06-30 FY2016 | — | $-0.01 | — | |
2015-06-30 FY2015 | 19.27x | $0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Antisense Therapeutics Limited (ATHJF) measures how much investors pay for each dollar of the company's trailing earnings. ATHJF's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.01.
Frequently asked questions
ATHJF pe ratio · 6 questionsATHJF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.01 and TTM EPS of -$0.01. Data sourced from Financial Modeling Prep via ATHJF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Antisense Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08